Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on December 30, 2010, by Emergent BioSolutions Inc. The report details a material definitive agreement entered into by Emergent BioDefense Operations Lansing Inc., a wholly-owned subsidiary of the registrant.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The reported transaction is a no-cost modification to an existing contract.
Material Changes
On December 30, 2010, the subsidiary entered into a no-cost modification of a contract dated September 25, 2007, with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services. Key changes include:
- Extension of the period of performance from December 31, 2010, to March 31, 2011.
- Extension of the delivery date for certain specified line items and milestone deliverables to March 31, 2011.
- The deliverables relate to a post-exposure prophylaxis (PEP) indication for BioThrax(R).
- The modification incurs no additional cost to the government or the company.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or discussion of new risks and contingencies beyond the contract extension. No unusual items were reported.
Investor Verification Points
- Verify the specific line items and milestone deliverables for BioThrax(R) affected by the extension.
- Confirm the impact of the extended delivery date on the company's revenue recognition schedule for the 2011 fiscal year.
- Review the original September 25, 2007, contract terms to understand the full scope of the BARDA agreement.